Press releases
First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study
EG 427 Announces Attendance at Conferences in H1 2024
EG 427 Announces New Preclinical Results from Multiple Studies of EG110A in NDO and OAB
EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters
EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder
EG 427 to hold poster presentation on lead asset EG110A at ESGCT
EG 427 announces attendance to multiple upcoming conferences in fall 2023
EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting
EG 427 announces final Series A closing, achieving €18 million in total funds raised
EG 427 announces that Dr. Greg Sarek, VP Research will be presenting at the 3rd annual Next Generation Gene Therapy Vectors conference
EG 427 appoints Ralph Laufer as new member to Board of Directors
EG 427 announces attendance to multiple upcoming conferences
EG 427 announces attendance to multiple upcoming conferences in Europe and US.
EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment.
EG 427 announces issuance of the first 2 patents in Europe and Japan protecting its first product EG110A.
EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board
EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board
EG 427 appoints Chief Medical Officer
EG 427 announces the appointment of Cornelia Haag-Molkenteller as Chief Medical Officer
EG 427 completes Series A financing
EG 427 announces €12 million Series A financing to advance its HSV-1 based gene therapy
Appointment of new VP of Research
EG 427 appoints Grzegorz Sarek, Ph.D., as Vice President of Research
News
l'Echo - about EG 427
Pharmaceutiques - Article on EG110A
Bladder Buzz talks about our innovative approach to NDO
EG 427 - a success story
EG 427 is the success story of the month presented by The SATT Network.
EG 427 wins key funding from Bpifrance
EG 427 received 360 000 € from Bpifrance to advance the pharmaceutical development of its first gene therapy candidate.
EG 427 recognised in iLab 2020
Events
EG 427 to present at Next Generation Gene Therapy Vectors 2024
2024-05-24
EG 427 at BIO International conference 2024
2024-05-14
EG 427 at BIO CEO and Investors 2024
2024-02-26
EG 427 at JP Morgan 2024
2023-12-18
EG 427 will be presenting at BioFuture
2023-09-26
EG 427 to present at East/West Biopharm conference
2023-09-18
EG 427 at International Continence Society 2023
2023-09-18
EG427 at BIO 2023
2023-09-18
Meet us at BIO €quity in Dublin
2023-09-18EG 427 will be presenting at BIO Europe Spring 2023
2023-02-07
See you at BioFIT 2022!
2022-11-14We'll be in BioFIT in Strasbourg on November 29-30, 2022. Our CEO, Philippe Chambon, will be presenting the company in the Startup Slam.
Come and meet us to learn more about nrHSV-1.
EG427 will be presenting at Bio-Europe Spring 2022
2022-11-04Attend our presentation to know more about the company. Looking forward to e-meet you there!
Meet us at Cell Gene Med 2022 in Barcelona
2022-11-04Our CEO, Philippe Chambon MD, PhD will be presenting EG 427 and our gene therapy platform.
